Bayer's April Crossroads: A Legal Gamble and a Clinical Breakthrough

Bayer's stock rally hinges on April events: a landmark stroke drug trial success, a Supreme Court glyphosate case, and the AGM. Key for future growth and legal liabilities.

Bayer shares, trading around €40, have staged a remarkable recovery from lows near €21. This rally now faces a critical test in late April, a fortnight packed with events that could define the company’s trajectory for years to come.

The catalyst for recent optimism stems from a long-awaited clinical victory. Full results from the Phase III OCEANIC-STROKE trial, published in the New England Journal of Medicine, show the Factor XIa inhibitor asundexian reduced ischemic strokes by 26% compared to a placebo. Crucially, the drug did not increase the risk of major bleeding. For the most severe outcomes—disabling or fatal strokes—the reduction was an even more significant 31%, with events occurring in just 2.1% of treated patients. This data marks a pivotal moment for Bayer’s pharmaceutical pipeline, coming nearly three years after the related OCEANIC-AF study was halted for lack of efficacy.

The scientific community is taking note. OCEANIC-STROKE is the first completed Phase III trial of an FXIa inhibitor for secondary stroke prevention, a field where previous approaches failed due to either insufficient efficacy or bleeding complications. The study involved over 12,000 patients globally. Bayer is now preparing regulatory submissions, with the U.S. FDA having already granted asundexian Fast Track status. The drug is central to management’s strategy of returning the pharmaceuticals division to mid-single-digit growth from 2027 onward.

This clinical success arrives just ahead of two major calendar events. On April 24, the company holds its Annual General Meeting. Shareholders will vote on board appointments and are set to receive an unchanged dividend of €0.11 per share for the 2025 fiscal year. The supervisory board will see changes, with Marcel Smits and Alfred Stern nominated to replace departing members Paul Achleitner and Colleen Goggins.

Three days later, on April 27, the U.S. Supreme Court will hear arguments in a case with profound implications for Bayer’s legal liabilities. The company contends that the federal FIFRA law preempts state-level failure-to-warn claims regarding its glyphosate-based weedkiller Roundup. A favorable ruling could strip tens of thousands of pending lawsuits of their legal foundation, potentially removing a major overhang on the stock. The outcome will significantly influence how much of Bayer’s financial resources continue to be consumed by litigation. The company’s net financial debt stood at just under €30 billion at the end of 2025, already 8.5% lower than the previous year.

Amid these pivotal events, Bayer’s leadership maintains a steady operational course. The financial forecast for 2026 remains unchanged, targeting currency-adjusted sales of €45 to €47 billion and EBITDA before special items between €9.6 and €10.1 billion. The company has also indicated that new U.S. pharmaceutical tariffs are fully accounted for in its current 2026 planning.

Beyond asundexian, another drug is showing explosive growth. Kerendia, which recently received a new EU approval for heart failure, saw currency-adjusted sales surge 88% last quarter. Management has set a long-term sales target exceeding €3 billion for this product alone.

The coming weeks will reveal whether Bayer’s operational momentum and pipeline promise can finally outweigh its legal burdens. First-quarter results due in May will provide the next check on whether the confirmed annual guidance is backed by solid day-to-day performance. For now, investors are watching a stock whose fate hinges on both a courtroom in Washington and clinical data in a medical journal.